Clinical tools for Community Oncologists Adjuvant abemaciclib, ribociclib or olaparib: who qualifies? A practical reference for community oncologists—comparing tumour biology and recurrence-risk criteria in monarchE, NATALEE and OlympiA, including CPS+EG scoring. #BreastCancer #Oncology

Molecular Oncology in Clinics FGFR inhibitors and hyperphosphataemia: a class effect. An on-target but outside the tumour effect of FGFR pathway inhibition. #MolecularOncologyInClinics #FGFR

Molecular Oncology in Clinics FGFR2 fusions and rearrangements in cholangiocarcinoma. A distinct subgroup of intrahepatic cholangiocarcinoma with a clinically actionable target. #MolecularOncologyInClinics #FGFR #Cholangiocarcinoma

Molecular Oncology in clinics FGFR alterations : span FGFR 1 to 4 and include mutations, fusions and amplifications. Frequency and clinical significance vary across tumour types. #MolecularOncologyInClinics #FGFR #BladderCancer

PICC: A PICC can make repeated chemotherapy and intravenous treatments easier and more comfortable—but patients and families often have questions about what it is and how it is cared for. #Chemotherapy #Cancer

Chemotherapy PORT Whenever there is discussion about PORT during cancer treatment planning , it’s often difficult for patients and care givers to visualise what PORT is or is it useful. This Reel ( video ) can help us understand what is PORT, where is it placed and how is it used. #Chemotherapy #CancerTreatment (Please unmute the video before viewing)

How does immunotherapy help our own immune system fight cancer? Explained simply for patients and families.

Molecular Oncology in Clinics POLE mutation- biomarker of excellent prognosis #MolecularOncologyInClinics

Molecular Oncology in Clinics Ever wondered what the relation is between p16 and HPV? As a student, I always had this doubt. Here’s a simple visual explanation. #MolecularOncologyInClinics #HPV

Molecular Oncology in Clinics Tumour Mutation Burden ( TMB ) - interpretation beyond just a number How TMB is measured matters. tTMB ≠ bTMB. Assay, genomic coverage and cut-offs matter. #MolecularOncologyInClinics #TMB #PrecisionOncology

Molecules Oncology in Clinics Liquid biopsy NGS - Reading beyond the mutation list is essential

Molecular Oncology in Clinics RNA splicing Oncogenic alterations don’t arise from coding mutations alone—they result from aberrant RNA splicing! 🧬 MET exon 14 skipping

Molecular Oncology in Clinics Concept of in-frame fusions

Molecular Oncology in Clinics Fusions and translocations!

Molecular Oncology in Clinics Understanding RNA NGS fusion better…

Molecular Oncology in Clinics A germline mutation is the beginning of the story—not the end! Tumour-specific biallelic loss creates HR deficiency, enabling synthetic lethality with PARP inhibitors. #MolecularOncology #HRD #PARPi